Journal: npj Imaging
Article Title: Bridging preclinical and clinical fluorescence-guided surgery with advanced cancer vision goggles
doi: 10.1038/s44303-026-00170-x
Figure Lengend Snippet: a Excitation and emission spectra of LS301 and preclinical FGS workflow (created with Biorender). b – e , Representative composite images showing pseudocolored NIR fluorescence overlaid on grayscale brightfield images of BALB/c mice ( n = 3) bearing subcutaneous 4T1 tumors ~24 h after intravenous injection of LS301-HSA (30 µM, 100 µL demonstrating FGS for tumor resection acquired with: ( b ) CVG – inset numbers indicate real-time quantitative fluorescence values at various signal thresholds; ( c ) Pearl – color scale [min = 4.70 × 10⁻², max = 3.22 × 10⁻¹]; ( d ) IVIS – color scale [min = 350, max = 2000]; ( e ) Quest Spectrum (Quest) – non-quantitative handheld imaging of dorsal flank regions. Panels from left to right show pre-surgery, exposed tumor after skin deflection, the post-resection, and after incision closure. Ex vivo imaging includes intact tumor (superficial—front; deep—back side), as well as 1.5-mm thick tumor slices. Tumor regions were delineated freehand based on fluorescence intensity and designated by dotted orange lines. f TNRs for CVG, Pearl, and IVIS were not significantly different, while CVG showed significantly higher TNR compared to Quest Spectrum ( P = 0.016). The red-circled area indicates the tumor ROI, while the white-circled area indicates the nontumor ROI in ( b – e ), which were selected for the TNR analysis. Data represent mean ± SD of TNRs from three mice. P values were calculated using one-way ANOVA with multiple comparisons in Prism 8.0.1. Scale bar: 5 mm.
Article Snippet: To evaluate the performance of CVG fluorescence detection in the OR setting, we compared the CVG platform to the FDA-approved Stryker SPY-PHI handheld FGS device, imaging resected tumor tissues from patients undergoing head and neck cancer surgery (Fig. ).
Techniques: Fluorescence, Injection, Imaging, Ex Vivo